5100 XIZANG (01115) grants distribution rights for the Southeast Asia and Middle East markets to a Malaysian company.
5100 Glacier (01115) announced that following several of the Group's seafood products obtaining halal certification in Malaysia, the Group's overseas strategic layout has made new progress. On August 19, 2026, Jafuli Investment Co., Ltd. (Jafuli) (a wholly-owned subsidiary of the Company) entered into a distribution agreement (the Distribution Agreement) with Landmark Holding Sdn. Bhd. (a limited liability company registered in Malaysia) (the Distributor), granting the Distributor exclusive distribution rights for 5100 Tibet Glacier Mineral Water products (the Products) in Malaysia, as well as general distribution rights for exports to several Southeast Asian and Middle Eastern markets.
5100 XIZANG (01115) announced that following the acquisition of halal certification for several of its aquatic products in Malaysia, the group's overseas strategic layout has made new progress. On August 19, 2026, Jiafuli Investment Co., Ltd. (Jiafuli) (a wholly-owned subsidiary of the company) entered into a distribution agreement (the Distribution Agreement) with Landmark Holding Sdn. Bhd. (a limited company registered in Malaysia) (the Distributor), granting the Distributor exclusive distribution rights for 5100 Xizang Glacier Mineral Water products (the Products) in Malaysia, as well as general distribution rights for export to several Southeast Asian and Middle Eastern markets.
This collaboration will lay the foundation for the group's products to enter the high-end drinking water market in Southeast Asia and the Middle East, which possesses significant growth potential, thereby enhancing the brands influence and competitiveness in the international market. The group will continue to seize overseas opportunities and accelerate its market expansion overseas.
Related Articles

Jiangsu Hengrui Pharmaceuticals (01276): Tian Fei has been appointed as the Secretary of the Board.

Jiangsu Hengrui Pharmaceuticals (01276) plans to repurchase 1 billion to 2 billion yuan of A-shares for the A-share employee stock ownership plan.

The world's first mRNA tumor vaccine meets phase three standards, and Sidis Pharmaceuticals (01244) rises 17% as it is re-evaluated against international benchmarks.
Jiangsu Hengrui Pharmaceuticals (01276): Tian Fei has been appointed as the Secretary of the Board.

Jiangsu Hengrui Pharmaceuticals (01276) plans to repurchase 1 billion to 2 billion yuan of A-shares for the A-share employee stock ownership plan.

The world's first mRNA tumor vaccine meets phase three standards, and Sidis Pharmaceuticals (01244) rises 17% as it is re-evaluated against international benchmarks.

RECOMMEND





